Table 1.
Characteristics of subjects included in and excluded from the cardiac correlative studies on AAML1421.
| Subjects included in cardiac analyses | Subjects excluded from cardiac analyses | |||
|---|---|---|---|---|
| N or median | % or range | N or median | % or range | |
| Total | 25 | 13 | ||
| Age at study entry in years | 12.5 | (1.81–21.5) | 8.1 | (1.93–21.2) |
| Gender | ||||
| Male | 14 | 56% | 4 | 31% |
| Female | 11 | 44% | 9 | 69% |
| Race | ||||
| Black or African American | 1 | 5% | 3 | 30% |
| White | 19 | 95% | 7 | 70% |
| Other or unknown | 5 | 20% | 3 | 23% |
| Ethnicity | ||||
| Hispanic | 5 | 20% | 2 | 15% |
| Not hispanic or unknown | 20 | 80% | 11 | 85% |
| Duration of first remission | ||||
| <180 days | 4 | 16% | 1 | 8% |
| 180–365 days | 13 | 52% | 6 | 46% |
| >365 days | 8 | 32% | 6 | 46% |
| Prior hematopoietic stem cell transplant | 7 | 28% | 3 | 23% |
| Weight category | ||||
| Underweight | 1 | 4% | 0 | 0% |
| Healthy weight | 15 | 60% | 7 | 54% |
| Overweight | 3 | 12% | 3 | 23% |
| Obese | 6 | 24% | 3 | 23% |
| Cumulative anthracycline exposure at enrollment (mg/m2 in daunorubicin equivalents) | 348 | (105–444) | 311 | (150–444) |
| Site reported ejection fraction at study entry | ||||
| Measurement available | 22 | 88% | 13 | 100% |
| Median (range) | 62% | (55%–71%) | 63% | (54%–76%) |
| Grade 3+ infection during cycle 1 | 13 | 52% | 4 | 31% |